Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA should loosen efficacy standards for "harmless" products, lawyer tells Hill hearing.

This article was originally published in The Tan Sheet

Executive Summary

FDA EFFICACY STANDARDS FOR "HARMLESS" PRODUCTS should be loosened, Houston-based lawyer Richard Jaffe suggested at a July 25 House Commerce/oversight subcommittee hearing on allegations of FDA retaliation. "The law, regulations, and their implementation must include a harm or risk analysis as a factor in drug approval," Jaffe declared. "Of course, this may result in some harmless but ineffective products coming on to the market," Jaffe declared. However, he maintained that "more often than not the marketplace itself can separate the wheat from the chaff."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel